FUTURE SUPPLY MODELS A
s insulin prices continue to soar, the advent of e-commerce drug manufacturers could provide a path to cheaper insulin. But a reluctance to shift from traditional prescription models – and uncertainty over a burgeoning black market obstacles.
announced plans to produce and distribute
Still, as COVID-19 opens the door to non-
New technology drives changes As telehealth shifts the geographical patients could look at alternative ways to Though patients seeing local providers
50 | Clinical Trial Supply Handbook
clinical trials that could translate to real-world
directly shipped to patients is as effective as insulin purchased and stored in traditional In addition, an increase in wearable The growing popularity of continuous glucose
Effect of rising prices Recent pricing data for the analogue insulins like these that could drive patients to
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56